Stock report · Delisted · Nasdaq
Regulus Therapeutics Inc (RGLS)
8.14USD Delisted Final close · Jun 23, 2025
RGLS no longer trades. Regulus Therapeutics was delisted from the Nasdaq in June 2025.
All prices on this page are historical. The last trade was on June 23, 2025, at $8.14.
RGLS stock price history
Final trading statistics
- Final close
- $8.14
- Final trading day
- Jun 23, 2025
- Market cap at delisting
- $563.57M
- Shares outstanding
- 69.23M
- Final 52-week range
- $0.83 – $8.35
- Avg. volume (final 3 mo.)
- 2,553,676
- All-time high
- $2649.60 · Nov 2014
- All-time low
- $0.79 · Mar 2023
- Return since IPO
- -98.4%
- Beta
- 0.37
- Book value / share
- $1.04
- Price / book
- 7.82
About Regulus Therapeutics Inc
Regulus Therapeutics developed drugs that block faulty microRNA targets, aimed at patients with genetic orphan diseases. Its lead program was farabursen, an anti-miR oligonucleotide that targets miR-17 for autosomal dominant polycystic kidney disease. It also had preclinical programs built on delivery methods that target specific organs.
First organized as Regulus Therapeutics LLC, it became Regulus Therapeutics Inc. in January 2009. The company was incorporated in 2007 and based in San Diego, California, and as of June 25, 2025 it became a subsidiary of Novartis AG. Its stock was delisted from the Nasdaq in June 2025, with the final trade on June 23, 2025 at $8.14.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Diego, CA
- Employees
- 34
- IPO date
- October 4, 2012
- Delisted
- June 23, 2025
- SEC CIK
- 1505512
Regulus Therapeutics financials before the delisting
The last 5 fiscal years Regulus Therapeutics reported as a public company, fiscal year ending December.
RGLS revenue and net income
RGLS earnings per share
RGLS annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | −$46.4M | −$0.87 |
| FY2023 | $0.00 | −$30.0M | −$1.59 |
| FY2022 | $0.00 | −$28.3M | −$1.90 |
| FY2021 | $10.0K | −$27.8M | −$3.30 |
| FY2020 | $10.01M | −$15.3M | −$5.50 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Regulus Therapeutics stock FAQ
What happened to Regulus Therapeutics stock?
Regulus Therapeutics was delisted from the Nasdaq in June 2025. The final close was $8.14 on June 23, 2025.
Can I still buy RGLS stock?
No. RGLS is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on June 23, 2025.
What was the last price of RGLS?
RGLS last closed at $8.14 on June 23, 2025, which valued the company at about $563.57M.
How did Regulus Therapeutics do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Regulus Therapeutics reported revenue of $0.00 and net income of −$46.4M.
When did Regulus Therapeutics go public?
Regulus Therapeutics shares started trading on October 4, 2012.
RGLS no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.